Merck Sharp + Dohme Corp.

Merck Sharpe & Dohme Corp.

Peizhi (Peter) Luo

Yan Li

Pingyu Zhong

Feng Dong

Rose M Cubbon

Holly A Hammond

Jon H Condra

Kevin Caili Wang

Ayesha Sitlani

Jeffrey T Blue

Laurence B Peterson

Shilpa Pandit

Joseph C Santoro

Denise K Nawrocki

Dana D Wood

Henryk Mach

Heidi Pixley

Sonia M Gregory

Timothy McCabe

Laura Orsatti

Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

1B20 PCSK9 antagonists

1D05 PCSK9 antagonists

Growing community of inventors

Lansdale, PA, United States of America

Peizhi (Peter) Luo